Chemoradiotherapy of stage III small-cell lung cancer: Can we further optimize multimodal treatment of N3 disease based on current evidence?
Clin Respir J
.
2018 Oct;12(10):2534-2535.
doi: 10.1111/crj.12951.
Authors
Chukwuka Eze
1
,
Olarn Roengvoraphoj
1
,
Nina-Sophie Schmidt-Hegemann
1
,
Lukas Käsmann
1
,
Maurice Dantes
1
,
Farkhad Manapov
1
Affiliation
1
Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
PMID:
30073781
DOI:
10.1111/crj.12951
No abstract available
Publication types
Letter
MeSH terms
Carcinoma, Non-Small-Cell Lung / therapy*
Chemoradiotherapy
Clinical Trials as Topic
Evidence-Based Medicine
Humans
Lung Neoplasms / therapy*
Neoplasm Staging
Practice Guidelines as Topic
Treatment Outcome